Skyrizi
Chemical Name | risankizumab-rzaa |
Dosage Form | Injection (subcutaneous; 75 mg/0.83 mL) |
Drug Class | Monoclonal antibodies |
System | Skin |
Company | AbbVie Inc. |
Approval Year | 2019 |
Indication
- Skyrizi is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.